BGI Changes Direction at Complete Genomics; Cuts Staff

BGI, the Shenzhen-based genomics sequencing company, has re-purposed its US subsidiary, Complete Genomics of Mountain View, California, and ordered significant staff reductions. When BGI bought CG in 2013, CG was a service provider, offering its Long Fragment Read technology for whole genome sequencing, which CG claimed provided more accurate readings. As recently as a month ago, CG's mission was to support commercial launch of its $12 million Revolocity genomic sequencer, a large, powerful machine with 200-300 potential global customers. Now, CG will support BGI's BGISEQ-500, a smaller desktop sequencer. More details.... Share this with colleagues: // //